Kornimate/medical-research-clean huggingface dataset:
taes for fpvcs: a pragmatic, randomized controlled trial

Conditions: Premature Ventricular Complexes

Summary: this prospective, randomized controlled trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (tavns) for patients with frequent premature ventricular coomplexes (fpvcs). ninety participants will be randomized to tavns group and sham-tavns group with the ratio of 1:1. they will receive tavns plus usual care or sham-tavns plus usual care for 6 weeks, and then be followed up for 12 weeks after the treatment. the primary outcome was the proportion of participants with a 50% decrease of the 24 hour (24h) premature ventricular complexes (pvcs) after 6-week treatment. secondary outcomes include the proportion of participants with a 75% decrease of the 24h-pvcs; the decrease from baseline of 24h-pvcs, total 24h-heartbeat, and the frequency of supraventricular arrhythmia; the score change from baseline in pvcs-related symptoms; the score change from baseline in sas and sds. subgroup analyses will be performed in age, gender, and the severity of pvcs. safety assessment will be documented during the whole trial.


Eligibility criteria:
inclusion criteria: * diagnosed as frequent premature ventricular contractions; * 2 ≤ lown level ≤ 4a; * 18 ≤ age ≤ 75; * volunteered to participant exclusion criteria: * severe valvular disease, congenital heart disease, pericardial disease, hypertrophic cardiomyopathy, unstable angina pectoris, acute myocardial infarction, myocarditis, aneurysm, congestive heart failure decompensation period (nyha grade iii or vi), cardiogenic shock, cerebrovascular disease, hematopoietic system disease, severe mental disease; * bradycardia, including pathologic sinus node syndrome, degree ii or greater atrioventricular block; * those who have already had pacemaker or percutaneous coronary intervention, or who plan to have pacemaker or percutaneous coronary intervention; * pregnant or lactating women; * local sensory deficit, or allergic to current; * may be allergic to percutaneous patches； * blood pressure ≤ 90/60 mmhg; * those who have participated in other clinical trials within 3 months.
primary care audit of global risk management

Conditions: Cardiovascular Diseases

Summary: 1. assessing the perception of canadian primary care physicians towards global cardiovascular risk assessment. 2. correlating physician perceptions to actual practice data, gathered via a retrospective chart audit. 3. evaluating the impact of a prospective educational and peer-practice pattern intervention on future assessment o cardiovascular risk and 4. assessing the role of carotid atherosclerosis assessment(carotid imt and plaque) as an adjunct to global risk prediction.

the majority of cardiovascular events occur in people with low to intermediate framingham risk score. despite evidence-based guidelines, the appropriate use of lipid-lowering therapies in this population remains limited and controversial. strategies to refine risk stratification in primary prevention have been poorly adopted. dissemination of practice-changing trials and closing the care gap in primary care remain a priority and a challenge. considerable confusion remains regarding the optimal application of lipid-lowering therapy in primary prevention. importantly, it remains largely unknown which tools or techniques are used by canadian primary care physicians to identify global vascular risk, and what barriers exist to implementing risk reduction therapies in such individuals. for primary prevention of patients with normal levels of ldl-cholesterol who are at increased risk on the basis of elevated hscrp, it remains unproven whether statin therapy will effectively reduce vascular event rates. the jupiter trial was launched in 2003 comparing rosuvastatin with placebo in 18,000 primary prevention patients with ldl-cholesterol of less than 3.36mm who also have an hscrp of greater than 2 mg/l. this trial has been stopped early due to unequivocal morbidity and mortality benefits in favor of the treatment strategy, and the final results will be available in early november, 2008. jupiter, once published, will require a major change in physician behavior with respect to screening and treating cardiovascular risk.

Eligibility criteria:
inclusion criteria: 1. men more than or equal to 40 yrs old and women more than or equal to 50 yrs old; 2. no previous history of atherosclerosis( angina, tia, myocardial infarction, stroke, peripheral arterial disease); 3. non-diabetic; 4. absence of lipid lowering treatment (current or past). exclusion criteria: 1. known history of atherosclerosis or diabetes; 2. use of lipid lowering therapies (statins, ezetimibe, fibrates, niacin, fish oil); 3. use of postmenopausal hormone replacement therapy; 4. use of immunosuppressant's or steroids; 5. active liver disease or hepatic dysfunction(alt\>2times the uln); 6. active renal disease (baseline creatinine \>170 umol/l); 7. history of malignancy within the past 5-years; 8. chronic inflammatory conditions such as arthritis, lupus or inflammatory bowel disease; 9. known alcohol or drug abuse; 10. failure to provide informed consent.

Keywords: assessing the perceptions of canadian primary care physicians towards global cardiovascular risk assessment.
limosilactobacillus reuteri as an adjuvant in the treatment of peri-implant mucositis

Conditions: Peri-implant Mucositis

Summary: mechanical debridement is the traditional method for the treatment of peri-implant mucositis and its success depends on the patient's correct oral hygiene. it is believed that probiotics may help by their ability to modulate the oral biofilm, resulting in anti-inflammatory and anti-bacterial plaque action. the aim of this study is to evaluate the adjuvant effect of the probiotic limosilactobacillus reuteri in the mechanical treatment of peri-implant mucositis. this study aims to include 32 subjects with implant-supported total rehabilitation and peri-implant mucositis, divided into test and control groups, equally subjected to professional mechanical debridement, with the administration of a daily gum® periobalance® lozenge for 30 days added to the test group. plaque index, bleeding index and probing pocket depth are evaluated before the intervention (baseline) and at 6 and 10 weeks later.


Eligibility criteria:
inclusion criteria: (i) dental implants placed for at least 12 months according to the all-on-4® concept; (ii) removal of the dental prosthesis as part of the conventional implant maintenance protocol; (iii) modified bleeding index19 score \>0 in at least one implant in the studied rehabilitation; (iv) implants connected to the prosthesis by means of transepithelial abutments; (v) if there were natural teeth in opposing arch, they were periodontally healthy or had been treated for periodontitis and were on periodontal support with residual pockets ≤5mm; (vi) demonstrated previous compliance with oral hygiene appointments; (vii) read and signed the informed consent. exclusion criteria: (i) peri-implantitis proven clinically (implant mobility, suppuration and/or pocket depth (pd) ≥5mm) and/or radiographically (bone remodeling greater than 2mm in the first year of function20 and mean marginal bone loss greater than 0.2mm for each subsequent year21 in the rehabilitated arch that was intended to be studied); (ii) clinically active peri-implantitis (mobility, suppuration and/or pd ≥5mm) in the opposing arch to the one intended to be studied; (iii) presence of an extra-maxillary/zygomatic implant in the rehabilitated arch that was intended to be studied; (iv) current probiotic supplementation; (v) diabetes mellitus not controlled by medication; (vi) current use of oral hygiene products containing chlorohexidine or essential oils; (vii) special needs individuals who depended on others for their oral hygiene and medication uptake.

Keywords: probiotic limosilactobacillus reuteri dental implant peri-implant mucositis total rehabilitation mechanical therapy nonsurgical treatment
effect of retatrutide compared with placebo in participants with type 2 diabetes and moderate or severe renal impairment, with inadequate glycemic control on basal insulin, with or without metformin and/or sglt2 inhibitor (transcend-t2d-3)

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with type 2 diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (sglt2) inhibitor. the study will last about 14 months and may include up to 22 visits.


Eligibility criteria:
inclusion criteria: * have type 2 diabetes (t2d) * have hba1c ≥7.0% (53 millimoles per mole (mmol/mol)) to ≤10.5% (91 mmol/mol) * have moderate or severe renal impairment * have been on the following stable diabetes treatment during 90 days prior to screening * basal insulin (≥20 international units (iu)/day) with or without * metformin and/or sglt2 inhibitor * are of stable weight for at least 90 days prior to screening * have a body mass index (bmi) ≥23.0 kilograms per meter squared (kg/m2) exclusion criteria: * have type 1 diabetes (t1d) * have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening * have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * have a history of unstable or rapidly progressing renal disease * have a prior or planned surgical treatment for obesity * have new york heart association functional classification iii or iv congestive heart failure * have had acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening * have a known clinically significant gastric emptying abnormality * have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years * have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (men) syndrome type 2. * have any lifetime history of a suicide attempt * had chronic or acute pancreatitis * have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening

Keywords: glucose metabolism disorders metabolic diseases endocrine system diseases diabetes mellitus diabetes mellitus, type 2 kidney disease renal insufficiency chronic
cardiac output autonomic stimulation therapy for acute heart failure (coast-ahf)

Conditions: Heart Failure Acute

Summary: a feasibility study to investigate the safety and performance of the neurotronik cardiac autonomic nerve stimulation (cans) therapy system

a single-arm, safety study intended to assess safety and system performance, and the feasibility to improve hemodynamics in patients with acute heart failure syndrome using transvenous, cardiac autonomic nerve stimulation (cans) therapy. in addition, the effects of neurotronik cans therapy™ on the congestion of patients will be studied. the study proposes that the neurotronik cans therapy™ system be deployed during the acute heart failure syndrome hospital admission, along with existing standard treatment.

Eligibility criteria:
inclusion criteria: 1. left ventricular ejection fraction \< 40%, measured in the last year 2. at least two of the following: * pulmonary capillary wedge pressure \> 18 mmhg * pulmonary congestion on chest x-ray * jugular vein distension * pulmonary rales * edema * dyspnea at rest * two (2) emergency room visits or hospital admissions in the past three (3) months, or three (3) emergency room visits or admissions in the past six (6) months requiring intravenous diuretics, ultrafiltration or in-hospital inotropic therapy. 3. with or without evidence of low perfusion exclusion criteria: 1. systolic blood pressure \ 160 mmhg 2. catecholamine or inotropic therapy within the previous 48 hours 3. levosimendan within the previous 72 hours 4. chronic outpatient catecholamine or inotropic therapy 5. presence of implanted pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy device 6. presence of or prior vagal nerve stimulator 7. coronary artery bypass graft surgery, percutaneous coronary intervention, acute myocardial infarction, or valve replacement within prior 1 month 8. second or third degree heart block 9. history of atrial or ventricular arrhythmias 10. history of mitral or aortic valve stenosis or regurgitation 11. hypertrophic obstructive or infiltrative cardiomyopathy 12. prior vagotomy 13. prior heart transplant 14. narrow angle glaucoma 15. renal failure - either on dialysis or serum creatinine \> 2.0 mg/dl 16. hepatic failure - bilirubin, serum glutamic oxaloacetic transaminase, or serum glutamic pyruvic transaminase \> four times upper limit of normal 17. life expectancy \< 12 months per physician judgment 18. women who are pregnant 19. allergy to fentanyl, midazolam, propofol, eggs, egg products, soybeans, or soy products 20. subjects unwilling or unable to provide consent

Keywords: electrical stimulation therapy electrodes parasympathetic nervous system sympathetic fibers post ganglionic congestive heart failure heart failure
mindfulness training for seniors

Conditions: Well Aging

Summary: the purpose of this research study is to learn more about how mindfulness training may influence thinking and feeling.


Eligibility criteria:
inclusion criteria: * individuals who are between 60 and 95 years of age * individuals who are fluent english speakers * individuals who are able to adequately and independently use electronic devices, such as a laptop, computer, or tablet, and have an internet connection * individuals who are willing and able to consent to participate in the study exclusion criteria: * individuals who are cognitively impaired and not independent in daily activities, such as the use of the telephone, preparing meals * individuals with an active and untreated mental condition (e.g., bipolar disorder, major depression) and/or hospitalization for psychological/mental health issues within the last month.
minimal effective concentration of lidocaine in propofol lidocaine mixture for relief of pain on propofol injection

Conditions: Pain

Summary: the research will be carried out in order to determine the optimal lidocaine concentration in propofol lidocaine mixture to prevent pain on propofol injection during induction of general anesthesia using a modified dixon's up-and-down method. we hypothesized that focusing on lidocaine concentration and not dose could be more convenient and valuable to alleviate pain with propofol injection. patients \& methods include assessment of severity of pain on propofol injection using nine concentrations of lidocaine in lidocaine propofol mixture in asa i\&ii patients aged 16-60 years with excluxion of patients with history of drug allergy, hepatic or renal impairment, cardiac problems, neurologic deficits or psychiatric disorders. demographic data, type and duration of surgery, time for unconsciousness, volume of propofol-lidocaine mixture used, pain scale during injection, increase in heart rate and/or hand or forearm withdrawal during injection will be recorded and patient satisfaction (will be assessed in the recovery room after regaining consciousness),

the research will be carried out in order to determine the optimal lidocaine concentration in propofol lidocaine mixture to prevent pain on propofol injection during induction of general anesthesia using a modified dixon's up-and-down method. we hypothesized that focusing on lidocaine concentration and not dose could be more convenient and valuable to alleviate pain with propofol injection. patients \& methods include assessment of severity of pain on propofol injection using nine concentrations of lidocaine in in lidocaine propofol mixture in asa i\&ii patients aged 18-60 years with exclusion of patients with history of drug allergy, hepatic or renal impairment, cardiac problems, neurologic deficits or psychiatric disorders. demographic data, type and duration of surgery, time for unconsciousness, volume of propofol-lidocaine mixture used, pain scale during injection, increase in heart rate and/or hand or forearm withdrawal during injection, patient satisfaction (will be assessed in the recovery room after regaining consciousness),

Eligibility criteria:
inclusion criteria: * asa i \&ii * age 18 - 60 years exclusion criteria: * study drug allergy * hepatic or renal impairment * cardiac problem * neurologic deficits * psychiatric disorders
clinical criteria for a pathogen in term newborn suspected of neonatal sepsis

Conditions: Newborn Sepsis

Summary: neonatal early onset sepsis (eos) diagnosis is difficult due to lack of sensivity and specificity markers. the investigators conduced a restrospectif study to all term born infants born between 1 january and 31 december 2013 and hospitalized for suspect eos. the presence of neonatal symptoms at birth appears to be a useful clinical marker of probable neonatal eos.

neonatal early onset spesis (eos) remains animportant etiology of neonatal morbidity and mortality. neonatal early onset sepsis (eos) diagnosis is difficult due to lack of sensivity and specificity markers. diagnosis is difficults due to lack of sensivity and specificity markers. the investigators conduced a restrospectif study to all term born infants born between 1 january and 31 december 2013 and hospitalized for suspect eos.the objective of the study was to identify early clinical signs in newborn infants with suspected neonatal sepsis to differentiate a likely infection with pathogen bacteria in the gastric suction culture.the presence of neonatal symptoms at birth appears to be a useful clinical marker of probable neonatal eos.

Eligibility criteria:
inclusion criteria: * children born at the university hospital center in amiens between 1 january and 31 december 2013 and hospitalized in the neonatology department for suspicion of mfis exclusion criteria: * child born before 37 weeks of amenorrhea and / or having a failure in the birth room requiring immediate transfer to neonatal resuscitation or intensive care neonatology

Keywords: newborn neonatal spesis clinical sriteria
corneal collagen crosslinking for keratoconus and ectasia using riboflavin/dextran or riboflavin/methylcellulose

Conditions: Keratoconus; Corneal Ectasia

Summary: this study is being conducted to evaluate the safety and efficacy of isotonic riboflavin for corneal collagen crosslinking for keratoconus and corneal ectasia. will determine the safety and efficacy of corneal collagen crosslinking (cxl) performed with two different riboflavin formulations for reducing corneal curvature.

this study will determine the safety and efficacy of corneal collagen crosslinking (cxl) performed with two different riboflavin formulations for reducing corneal curvature. subjects will be randomized to one of 2 groups. one group will be treated with a methylcellulose riboflavin solution and the other group will be treated with a dextran riboflavin solution. both groups will be exposed to 3mw/cm2 of continuous uva light for a total of 30 minutes; each group will continue to be administered the designated riboflavin drops during uv exposure. the primary efficacy parameter that will be evaluated over time is maximum keratometry (kmax) in the randomized eyes for each treatment group. the secondary efficacy parameter will be to determine if the two treatment groups equivalent in their kmax change at 12 months after treatment compared with baseline.

Eligibility criteria:
inclusion criteria: * 12 years of age or older * having a diagnosis of keratoconus or corneal ectasia after corneal refractive surgery * presence of central or inferior steepening on the pentacam map * axial topography consistent with keratoconus or post-surgical corneal ectasia * contact lens wearers only: removal of contact lens for the required period of 1 week prior to the screening refraction * signed written informed consent * willingness and ability to comply with schedule for follow-up visits exclusion criteria: * eyes classified as either normal, atypical normal, or keratoconus suspect on the severity grading scheme * corneal pachymetry less than or equal to 300 microns at the thinnest point measured by pentacam in the eye(s) to be treated * previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example: history of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) clinically significant corneal scarring in the cxl treatment zone * a history of chemical injury or delayed epithelial healing in the eye(s) to be treated * pregnancy (including plan to become pregnant) or lactation during the course of the study * a known sensitivity to study medications * patients with nystagmus or any other condition that would prevent a steady gaze during the cxl treatment or other diagnostic tests * patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing

Keywords: keratoconus corneal ectasia collagen crosslinking riboflavin cornea ultraviolet crosslinking corneal crosslinking